. 2011 Dec 20;6(12):e28124. doi: 10.1371/journal.pone.0028124

Table 1. Signal detection for statin-associated muscular adverse events.

	Statins	N	PRR (kai2)	ROR (95% CI)	IC (95% CI)	EBGM (95% CI)
Myalgia	Pravastatin	518	3.047 (704.853)^*	3.062 (2.807, 3.316)^*	1.591 (1.465, 1.716)^*	3.000 (2.789)^*
	Simvastatin	1980	3.453 (3437.911)^*	3.524 (3.369, 3.678)^*	1.774 (1.710, 1.839)^*	3.418 (3.293)^*
	Atorvastatin	2456	3.503 (4383.844)^*	3.593 (3.450, 3.735)^*	1.795 (1.737, 1.853)^*	3.468 (3.354)^*
	Rosuvastatin	1693	9.439 (12420.824)^*	9.646 (9.185, 10.107)^*	3.193 (3.122, 3.263)^*	9.186 (8.825)^*
Rhabdomyolysis	Pravastatin	212	2.246 (145.068)^*	2.253 (1.968, 2.538)^*	1.152 (0.958, 1.347)^*	2.205 (1.967)
	Simvastatin	2278	7.210 (12122.472)^*	7.594 (7.278, 7.911)^*	2.830 (2.769, 2.891)^*	7.129 (6.887)^*
	Atorvastatin	1114	2.861 (1353.202)^*	2.915 (2.746, 3.084)^*	1.509 (1.423, 1.595)^*	2.840 (2.703)^*
	Rosuvastatin	605	5.994 (2492.472)^*	6.073 (5.602, 6.544)^*	2.558 (2.442, 2.674)^*	5.933 (5.546)^*
Increase of CPK	Pravastatin	206	2.461 (177.003)^*	2.470 (2.153, 2.787)^*	1.283 (1.085, 1.480)^*	2.410 (2.147)^*
	Simvastatin	1036	3.673 (2017.111)^*	3.755 (3.529, 3.981)^*	1.866 (1.777, 1.956)^*	3.641 (3.458)^*
	Atorvastatin	997	2.886 (1233.942)^*	2.942 (2.762, 3.122)^*	1.522 (1.431, 1.613)^*	2.865 (2.719)^*
	Rosuvastatin	505	5.634 (1908.004)^*	5.702 (5.220, 6.184)^*	2.469 (2.342, 2.596)^*	5.581 (5.182)^*

N: the number of co-occurrences.

PRR: the proportional reporting ratio [19], ROR: the reporting odds ratio [20], IC: the information component [21], EBGM: the empirical Bayes geometric mean [22].

CI: the confidence interval; two-sided for ROR and IC, and one-sided for EBGM.

*: signal detected, see “Methods” for the criteria of detection.

Myalgia, rhabdomyolysis and increase of creatine phosphokinase (CPK) level were coded as PT10028411, PT10039020 and PT10005470, respectively.